Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer

Masafumi Nakamura, Hiroshi Nakashima, Toshiya Abe, Takaaki Ensako, Koji Yoshida, Keisuke Hino

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aim: We investigated effects of gemcitabine-based adjuvant chemotherapy (GEM) on prognosis of patients with gallbladder cancer. Patients and Methods: We retrospectively analyzed outcomes of 36 patients who underwent radical resection for gallbladder cancer from 2001 through to 2012, using2 for prognostic factors and Kaplan-Meier estimator and log-rank tests for survival data. Results: The GEM group had higher rates of lymph node positivity and distant metastasis, higher UICC stage and fewer R0 resections; their 5-year survival rate (60%) did not significantly differ from that of the controls (70.0%), nor was GEM a significant prognostic factor in univariate analysis. However, among patients who underwent R1 and R2 resections, GEM significantly improved prognosis in both univariate and multivariate analyses. Median survival of the R1/2 GEM group (66.4 months) was significantly better than that of controls (5.4 months) (p=0.002). Conclusion: GEM improved prognosis of patients with gallbladder cancer after R1/R2 resections.

Original languageEnglish
Pages (from-to)3125-3130
Number of pages6
JournalAnticancer Research
Volume34
Issue number6
Publication statusPublished - Jan 1 2014
Externally publishedYes

Fingerprint

gemcitabine
Gallbladder Neoplasms
Adjuvant Chemotherapy
Survival
Multivariate Analysis
Survival Rate
Lymph Nodes
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Nakamura, M., Nakashima, H., Abe, T., Ensako, T., Yoshida, K., & Hino, K. (2014). Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer. Anticancer Research, 34(6), 3125-3130.

Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer. / Nakamura, Masafumi; Nakashima, Hiroshi; Abe, Toshiya; Ensako, Takaaki; Yoshida, Koji; Hino, Keisuke.

In: Anticancer Research, Vol. 34, No. 6, 01.01.2014, p. 3125-3130.

Research output: Contribution to journalArticle

Nakamura, M, Nakashima, H, Abe, T, Ensako, T, Yoshida, K & Hino, K 2014, 'Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer', Anticancer Research, vol. 34, no. 6, pp. 3125-3130.
Nakamura M, Nakashima H, Abe T, Ensako T, Yoshida K, Hino K. Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer. Anticancer Research. 2014 Jan 1;34(6):3125-3130.
Nakamura, Masafumi ; Nakashima, Hiroshi ; Abe, Toshiya ; Ensako, Takaaki ; Yoshida, Koji ; Hino, Keisuke. / Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer. In: Anticancer Research. 2014 ; Vol. 34, No. 6. pp. 3125-3130.
@article{a479aafb982e41d483d8c1f904c7e2bf,
title = "Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer",
abstract = "Aim: We investigated effects of gemcitabine-based adjuvant chemotherapy (GEM) on prognosis of patients with gallbladder cancer. Patients and Methods: We retrospectively analyzed outcomes of 36 patients who underwent radical resection for gallbladder cancer from 2001 through to 2012, using2 for prognostic factors and Kaplan-Meier estimator and log-rank tests for survival data. Results: The GEM group had higher rates of lymph node positivity and distant metastasis, higher UICC stage and fewer R0 resections; their 5-year survival rate (60{\%}) did not significantly differ from that of the controls (70.0{\%}), nor was GEM a significant prognostic factor in univariate analysis. However, among patients who underwent R1 and R2 resections, GEM significantly improved prognosis in both univariate and multivariate analyses. Median survival of the R1/2 GEM group (66.4 months) was significantly better than that of controls (5.4 months) (p=0.002). Conclusion: GEM improved prognosis of patients with gallbladder cancer after R1/R2 resections.",
author = "Masafumi Nakamura and Hiroshi Nakashima and Toshiya Abe and Takaaki Ensako and Koji Yoshida and Keisuke Hino",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "34",
pages = "3125--3130",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer

AU - Nakamura, Masafumi

AU - Nakashima, Hiroshi

AU - Abe, Toshiya

AU - Ensako, Takaaki

AU - Yoshida, Koji

AU - Hino, Keisuke

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Aim: We investigated effects of gemcitabine-based adjuvant chemotherapy (GEM) on prognosis of patients with gallbladder cancer. Patients and Methods: We retrospectively analyzed outcomes of 36 patients who underwent radical resection for gallbladder cancer from 2001 through to 2012, using2 for prognostic factors and Kaplan-Meier estimator and log-rank tests for survival data. Results: The GEM group had higher rates of lymph node positivity and distant metastasis, higher UICC stage and fewer R0 resections; their 5-year survival rate (60%) did not significantly differ from that of the controls (70.0%), nor was GEM a significant prognostic factor in univariate analysis. However, among patients who underwent R1 and R2 resections, GEM significantly improved prognosis in both univariate and multivariate analyses. Median survival of the R1/2 GEM group (66.4 months) was significantly better than that of controls (5.4 months) (p=0.002). Conclusion: GEM improved prognosis of patients with gallbladder cancer after R1/R2 resections.

AB - Aim: We investigated effects of gemcitabine-based adjuvant chemotherapy (GEM) on prognosis of patients with gallbladder cancer. Patients and Methods: We retrospectively analyzed outcomes of 36 patients who underwent radical resection for gallbladder cancer from 2001 through to 2012, using2 for prognostic factors and Kaplan-Meier estimator and log-rank tests for survival data. Results: The GEM group had higher rates of lymph node positivity and distant metastasis, higher UICC stage and fewer R0 resections; their 5-year survival rate (60%) did not significantly differ from that of the controls (70.0%), nor was GEM a significant prognostic factor in univariate analysis. However, among patients who underwent R1 and R2 resections, GEM significantly improved prognosis in both univariate and multivariate analyses. Median survival of the R1/2 GEM group (66.4 months) was significantly better than that of controls (5.4 months) (p=0.002). Conclusion: GEM improved prognosis of patients with gallbladder cancer after R1/R2 resections.

UR - http://www.scopus.com/inward/record.url?scp=84906324031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906324031&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 3125

EP - 3130

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6

ER -